Kevin S. Boyle, Sr
2022
In 2022, Kevin S. Boyle, Sr earned a total compensation of $1.8M as Chief Executive Officer at ZIOPHARM Oncology, a 61% decrease compared to previous year.
Compensation breakdown
| Bonus | $270,000 |
|---|---|
| Option Awards | $904,000 |
| Salary | $600,000 |
| Other | $18,818 |
| Total | $1,792,818 |
Boyle received $904K in option awards, accounting for 50% of the total pay in 2022.
Boyle also received $270K in bonus, $600K in salary and $18.8K in other compensation.
Rankings
In 2022, Kevin S. Boyle, Sr's compensation ranked 1,935th out of 5,736 executives tracked by ExecPay. In other words, Boyle earned more than 66.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,935 out of 5,736 | 66th |
Division Manufacturing | 1,031 out of 3,125 | 67th |
Major group Chemicals And Allied Products | 438 out of 1,416 | 69th |
Industry group Drugs | 401 out of 1,317 | 70th |
Industry Pharmaceutical Preparations | 289 out of 963 | 70th |
Source: SEC filing on April 25, 2023.
Boyle's colleagues
We found two more compensation records of executives who worked with Kevin S. Boyle, Sr at ZIOPHARM Oncology in 2022.